But now, the U.S. has ordered enough Paxlovid for 20 million people, enough to last for several months.
“They reduce the hospitalization rate by about 90%, so that’s a big benefit,” said Dr. Frank Rhame, an infectious disease physician at Allina Health. “We have a couple of other alternatives, but this one is the biggest benefit.”